Q1 2024 · 13F-HR
Novo Holdings A/Sholdings as filed
Filed 2024-05-15 · accession 0000950123-24-005208
$1.45B
Reported value
35
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N07059210 | ASML | ASML HOLDING N V | $177.1M | 12.2% | 182,536 | Common | SOLE |
| 11271J107 | BN | BROOKFIELD CORP | $162.5M | 11.2% | 3,880,230 | Common | SOLE |
| 79466L302 | CRM | SALESFORCE INC | $144.6M | 9.98% | 480,160 | Common | SOLE |
| 28035Q102 | EPC | EDGEWISE THERAPEUTICS INC | $115.7M | 7.98% | 6,344,430 | Common | SOLE |
| 218352102 | CORT | CORCEPT THERAPEUTICS INC | $60.7M | 4.19% | 2,411,362 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $57.7M | 3.98% | 845,000 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $51.4M | 3.55% | 1,098,600 | Common | SOLE |
| 12685J105 | CABO | CABLE ONE INC | $50.1M | 3.46% | 118,403 | Common | SOLE |
| 51655R101 | — | LANZATECH GLOBAL INC | $48.9M | 3.38% | 15,814,845 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $44.6M | 3.08% | 1,400,000 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $39.3M | 2.71% | 450,000 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $37.7M | 2.60% | 1,500,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $36.3M | 2.51% | 1,339,304 | Common | SOLE |
| 01609W102 | BABA | ALIBABA GROUP HLDG LTD | $36.2M | 2.50% | 500,827 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $34.0M | 2.35% | 358,626 | Common | SOLE |
| 037833100 | AAPL | APPLE INC | $31.4M | 2.16% | 182,960 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $29.4M | 2.03% | 2,500,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $28.3M | 1.95% | 1,050,000 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $27.9M | 1.92% | 1,250,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $27.0M | 1.86% | 1,168,030 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $26.6M | 1.83% | 2,000,000 | Common | SOLE |
| 113004105 | BAM | BROOKFIELD ASSET MANAGMT LTD | $26.4M | 1.82% | 627,207 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $25.7M | 1.77% | 1,638,298 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $19.3M | 1.33% | 1,100,000 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $19.2M | 1.33% | 1,077,140 | Common | SOLE |
| 59102M104 | MGX | METAGENOMI INC | $18.3M | 1.27% | 1,739,175 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $17.7M | 1.22% | 118,383 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $17.4M | 1.20% | 700,000 | Common | SOLE |
| 457730109 | INSP | INSPIRE MED SYS INC | $14.1M | 0.97% | 65,524 | Common | SOLE |
| 449778109 | IOBTQ | IO BIOTECH INC | $8.8M | 0.61% | 5,088,258 | Common | SOLE |
| 00288U106 | ABCL | ABCELLERA BIOLOGICS INC | $5.1M | 0.35% | 1,126,915 | Common | SOLE |
| 89455T109 | TMCI | TREACE MED CONCEPTS INC | $4.7M | 0.32% | 360,000 | Common | SOLE |
| 57142B104 | MQ | MARQETA INC | $2.6M | 0.18% | 441,558 | Common | SOLE |
| 36322Q107 | GLTOUSD | GALECTO INC | $1.9M | 0.13% | 2,497,791 | Common | SOLE |
| 84833T103 | SPRO | SPERO THERAPEUTICS INC | $806,511 | 0.06% | 468,902 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.